Abstract: A compound selected from those of formula (I): ##STR1## where RA, RB, RC, RD, A, n, X, Y and Ar are defined in the description, and a medicinal product comprising the same for treating a mammal afflicted with a disease associated with sigma receptors.

Abstract: The invention relates to a compound selected from those of formula (I): ##STR1## in which R.sub.1, R.sub.2, R.sub.3, X and n are as defined in the description, the optical isomers thereof, and the addition salts thereof with a pharmaceutically acceptable acid or base and medicinal product containing the same, useful for treating a mammal afflicted with a pathology associated with the sigma receptors.

Abstract: The invention relates to a compound selected from those of formula (I): ##STR1## in which R.sub.1, R.sub.2, R.sub.3, X and n are as defined in the description, the optical isomers thereof, and the addition salts thereof with a pharmaceutically acceptable acid or baseand medicinal product containing the same, useful for treating a mammal afflicted with a pathology associated with the sigma receptors.

Abstract: The invention relates to compounds of formula (I): ##STR1## wherein: R.sub.1 and R.sub.2 are selected, each independently of the other, from hydrogen and an alkyl radical,A is selected from the radicals: ##STR2## wherein: R.sub.3 represents a radical selected from halogen, alkyl, alkoxy, amino, 2-acetyl, alkylamino, dialkylamino, carboxy, alkoxycarbonyl, trifluoromethyl and cyano,R.sub.4, R.sub.5, R.sub.6, R.sub.7 and R.sub.8 are selected, each independently of the others, from hydrogen, a halogen, an alkyl, alkoxy, amino, alkylamino, dialkylamino, carboxy, alkoxycarbonyl, cyano and a trifluoromethyl radical,R.sub.

Abstract: A compound selected from those of formula: ##STR1## wherein: A-B, n, D and E are as defined in the specification,their racemic mixtures, and their optical isomers,and also the physiologically tolerable salts thereof with appropriate acids.The products of the invention may be used therapeutically.

Abstract: Compound of formula (I): ##STR1## and its addition salts with a pharmaceutically acceptable acid or base, a medicinal products containing the same are useful as partial agonist of the glycine B site.

Abstract: Bioadhesive pharmaceutical composition for the controlled release of active principles locally across the buccal cavity or systemically across a mucous membrane, wherein it is composed of an active principle, a compound (A), a compound (B) and excipients as defined in the description.

Abstract: A compound of formula (I): ##STR1## in which: R.sub.1, R.sub.2, which may be identical or different, represent hydrogen or halogen, or alkyl, alkoxy, nitro or trihalomethyl,X represents CO, SO.sub.2 or CH.sub.2,A.sub.1 represents any one of the groups as defined in the description,A.sub.2 represents --(CH.sub.2).sub.n or --CH.dbd.CH--,R.sub.3, R.sub.4, which may be identical or different, represent hydrogen or alkyl,its isomers as well as its addition salts with a pharmaceutically acceptable base and medicinal product containing the same are useful as angiogenesis inhibitors.

Abstract: The invention provides new compounds pertaining to the class of: 2-(aminocarbonylalkylcarbonyl)-5-phenylalkyllthiophene, enantiomers and physiologically tolerable salts thereof.For example:5-?4-(4-methylphenyl)butyl-2-{3,3-dimethyl-4-?N'-(2,3,4-trimethoxybenzyl)-N -piperazinylcarbonyl!butyryl}thiophene is described.Medicinal products containing the same are useful in the treatment of any pathology involving bone hyper-resorption.

Abstract: A compound selected from those of formula (I): ##STR1## where RA, RB, RC, RD, A, n, X, Y and Ar are defined in the description, and a medicinal product comprising the same for treating a mammal afflicted with a disease associated with sigma receptors.

Abstract: New compounds of formula: ##STR1## wherein A-B, X, Y, R and n are as defined in the description. The geometric isomers, racemate and optical isomers thereof and the addition salts with pharmaceutically acceptable acids, and medicinal products containing the same are useful for treating psychotic disorders, depression, Parkinson's disease, memory disorders and disorders associated with drug abuse.

Abstract: A compound selected from those of formula (I): ##STR1## in which A, R, Y, R.sup.1, R.sup.2 and R.sup.3 are as defined in the description,and a medicinal product containing the same useful for treating a disorder of the melatoninergic system.

Abstract: New compounds of formula: ##STR1## wherein: A-B, n and Y are as defined in the description,their optical isomers and physiologically tolerable salts thereof with appropriate acids.The products of the invention may be used as medicaments.

Abstract: Compounds of formula (I): ##STR1## in which: n represents 1 or 2,R.sub.1 represents hydrogen or alkyl, benzyl, acetyl, benzoyl, allyl, pyridinecarbonyl, pyridinemethyl, acylaminoalkyl (optionally substituted), pyridineaminocarbonyl, phthalimidoalkyl, thiochromanyloxyalkyl or (benzodioxanyloxy)alkyl,R.sub.2, R.sub.3 or R.sub.4, which may be identical or different, represent hydrogen or halogen or alkyl, alkoxy, hydroxyl, acetyl, aminocarbonyl, aminomethyl, cyano, nitro, amino, phenyl (which may or may not be substituted), furyl, pyridinyl, thienyl or pyridyl, or alternatively,when they are located on adjacent carbons, R.sub.2 and R.sub.3 form, with the carbon atoms which bear them, a furan or phenyl ring,the isomers thereof and the addition salts thereof with a pharmaceutically acceptable acid, and medicinal products containing the same are useful for the treatment of diseases requiring a ligand to the 5-HT.sub.2C receptors.

Abstract: A compound of formula (I): ##STR1## in which X, n, B and Y are as defined in the description. useful as cytokine inhibitors.

Abstract: The invention relates to the compounds of formula (I): ##STR1## in which: R.sub.1 represents alkyl, phenyl, naphthyl, pyridyl or thienyl group, each phenyl, naphthyl, pyridyl or thienyl optionally being substituted,R.sub.2 represents a hydrogen atom or a substituted or unsubstituted alkyl, substituted or unsubstituted phenyl, cycloalkyl, piperidino or substituted or unsubstituted amino group,X represents CO or SO.sub.2,R.sub.3 represents hydrogen or alkyl,R.sub.4 represents alkyl, substituted or unsubstituted phenyl or trihalomethyl, or else R.sub.3 and R.sub.4 form, together with the carbon atoms which carry them, cyclo(C.sub.3 -C.sub.7)alkenyl,A represents phenyl, naphthyl or pyridyl ring, each phenyl, naphthyl or pyridyl ring optionally being substituted,their isomers, the corresponding quaternary ammonium salts of the piperidine and their addition salts with a pharmaceutically acceptable acid, an medicinal products containing the same are useful as antagonists of NK.sub.1 receptors.

Abstract: Compounds of formula (I): ##STR1## in which: X represents --CH.sub.2 --, --(CH.sub.2).sub.2 --, --CH.dbd.CH--, --O--CH.sub.2 --, --S--CH.sub.2 --, --SO--CH.sub.2 -- or --SO.sub.2 --CH.sub.2 --,Y represents oxygen or sulfur or --NR.sub.5 --,R.sub.1 represents halogen, linear or branched (C.sub.1 -C.sub.6) alkyl (unsubstituted or substituted), hydroxyl or linear or branched (C.sub.1 -C.sub.6) alkoxy,R.sub.2 represents hydrogen or halogen, linear or branched (C.sub.1 -C.sub.6) alkyl (unsubstituted or substituted), hydroxyl, linear or branched (C.sub.1 -C.sub.6) alkoxy or linear or branched (C.sub.1 -C.sub.6) alkylthio,R.sub.3 represents hydrogen or halogen, linear or branched (C.sub.1 -C.sub.6) alkyl (unsubstituted or substituted), hydroxyl, linear or branched (C.sub.1 -C.sub.6) alkoxy or linear or branched (C.sub.1 -C.sub.6) alkylthio,R.sub.4 represents hydrogen or amino (unsubstituted or substituted)R.sub.5 represents hydrogen or linear or branched (C.sub.1 -C.sub.6) alkyl, or alternativelyR.sub.1 and R.sub.

Abstract: Compounds of formula (I): ##STR1## wherein: R is selected from the radicals: ##STR2## Y is selected from ##STR3## R.sub.1 represents the radical ##STR4## and A, B, C, D, R.sub.2, R.sub.3 and R.sub.4 are as defined in the description, and also the possible geometric isomers and/or diastereoisomers and/or enantiomers thereof in pure form or in the form of a mixture. The compounds of the present invention have a therapeutic use as a result of their angiogenesis-inhibiting activity.

Abstract: Compound of formula (I): ##STR1## in which: R.sub.1, R.sub.2 and R.sub.3, which are identical or different, represent hydrogen or halogen or alkyl, nitro, cyano or aminosulfonyl, or alternatively, when two of them are located on adjacent carbons, form, with the carbon atoms to which they are attached, (C.sub.3 -C.sub.7) cycloalkyl ring or substituted or unsubstituted benzene ring,R.sub.4 represents hydrogen, linear or branched (C.sub.1 -C.sub.6) alkyl, substituted or unsubstituted phenyl or a group ##STR2## in which R.sub.6 and R.sub.7, which are identical or different, represent hydrogen or substituted or unsubstituted, linear or branched (C.sub.1 -C.sub.6) alkyl,R.sub.5 represents hydrogen, hydroxyl, linear or branched (C.sub.1 -C.sub.6) alkoxy, phenoxy, mercapto, linear or branched (C.sub.1 -C.sub.6) alkylthio, substituted or unsubstituted, linear or branched (C.sub.1 -C.sub.6) alkyl, substituted or unsubstituted phenyl or substituted or unsubstituted amino, or a group ##STR3## in which R.sub.6 and R.sub.

Abstract: The invention relates to a compound selected from these of formula (I): ##STR1## in which R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5 and B are as defined in the description, their enantiomers and diastereoisomers, their Z and E isomers, and their addition salts with a pharmaceutically-acceptable acid or base, and medicinal products containing the same which is useful for treating a disorder selected from an inflammatory disorder and a pathological inflammatory condition.